Skip to main content
Clinical Trials/CTRI/2021/12/038578
CTRI/2021/12/038578
Completed
未知

A non-interventional, multicenter study to determine the prevalence of homologous recombination repair (HRR) gene mutations in patients with metastatic castration-resistant prostate cancer in India - PROSPECT

AstraZeneca Pharma India Ltd0 sites211 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
AstraZeneca Pharma India Ltd
Enrollment
211
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
May 29, 2023
Last Updated
last year
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Male participants aged \=18 \= 80 years of age.
  • 2\. Pathological mCRPC cases confirmed by laboratory (PSA and testosterone levels), X\-rays (optional),(CT scan/ MRI scan / PET scan) .
  • 3\. Availability of medical history (demographic information and history of cancer)
  • 4\. Participants who are able to provide written informed consent form (ICF).

Exclusion Criteria

  • 1\. Diagnosis of any severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of the study results.
  • 2\. Newly diagnosed mCRPC participants without tissue sample availability.

Outcomes

Primary Outcomes

Not specified

Similar Trials